EMA Recommends Non-Prescription Status for Opioid Overdose Nasal Spray Nyxoid

The European Medicines Agency's CHMP has recommended that Nyxoid (naloxone nasal spray) be made available without a prescription across all EU and EEA countries. This change in legal status aims to significantly broaden access to this emergency treatment for known or suspected opioid overdoses. Increased accessibility could help save lives by enabling faster intervention during overdose incidents.